期刊文献+

Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients 被引量:1

原文传递
导出
摘要 Li-Fraumeni syndrome(LFS),a rare autosomal-dominant inheritance condition,is associated with a family cancer history as well as pathogenic/likely-pathogenic TP53 germline variants(P/LP TP53 GV).The current clinical methods for detecting LFS are limited.Here,we retrospectively investigate P/LP TP53 GV among Chinese cancer patients by next-generation sequencing and evaluate its relationship with a family cancer history.A total of 270 out of 19,226 cancer patients have TP53 GV,including 53 patients with P/LP TP53 GV.Patients with P/LP TP53 GV are mainly found in male with glioma,lung cancer or sarcoma.The median age of diagnosis for P/LP TP53 GV patients is significantly lower than that of non-P/LP TP53 GV patients(31-years vs.53-years;P<0.01).One LFS patient and 3 Li-Fraumeni-like syndrome(LFL)patients are among the 26 followed-up P/LP TP53 GV patients.Among 25 types of P/LP TP53 GV,the highest variant frequencies occurred at codon 175 and 248.p.M237 I,p.R158 H,p.C238 Y and p.C275 R,are firstly identified among the Chinese LFS/LFL patients.This study reports the(P/LP)TP53 GV characteristics of Chinese pan-cancer patients.These findings suggest analyzing the P/LP TP53 GV in cancer patients is an effective strategy for identifying cancer predisposition syndrome.
出处 《Journal of Genetics and Genomics》 SCIE CAS CSCD 2022年第7期645-653,共9页 遗传学报(英文版)
  • 相关文献

参考文献1

二级参考文献77

  • 1Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer, 2009,9:550 - 562.
  • 2Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth andmetabolism. Nat Rev Genet, 2006,7:606-619.
  • 3Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle, 2004,3:1221-1224.
  • 4Samuels Y, Wang Z, Bardelli A mutations of the PIK3CA gene , et al. High frequency of n human cancers. Science.2004,304:554.
  • 5Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer, 2002,2:489-501.
  • 6Bader AG, Kang S, Zhao L, et al. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer, 2005,5:921-929.
  • 7Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and elF4E in oncogenesis and cancer therapy. Nature, 2004,428:332-337.
  • 8Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell, 2000,103:253-262.
  • 9Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5" cap. Nature, 1990,345:544-547.
  • 10Dan HC, Sun M, Yang L, et al. Phosphatidylinositol 3-kinase/ Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem, 2002,277: 35364-35370.

共引文献26

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部